ACE2 and COVID-19: A special report described the uncertain effect of renin-angiotensin-aldosterone system (RAAS) inhibition in humans due to the paucity of studies regarding the effect of RAAS inhibition on ACE2 expression confirming that RAAS inhibitors should be continued in hypertensive patients at risk for or with COVID-19 (51).